AIS Vistashares Artificial Intelligence Supercycle ETF

Antares Pharma, Inc. (NYSE Amex: AIS) today announced the appointment of LeRoux Jooste to the position of Senior Vice President of Pharmaceutical Sales and Marketing. Mr. Jooste has more than 25 years of experience in the biotech and pharmaceutical industry, including senior level leadership roles in global marketing, sales, new product development and commercial operations.

“We are very pleased to add LeRoux’s extensive commercial and new product planning experience to the Antares team,” said Paul K. Wotton, Ph.D, President and CEO. “LeRoux brings to Antares a proven track record in leading sales and marketing organizations, launching new products and managing alliance partners. In particular, LeRoux’s experience working at Cephalon will be beneficial to Antares as we continue to grow this Company in an intelligent and focused way.”

“It’s an exciting time to be joining the Antares organization,” said Mr. Jooste. “The Company is currently working to commercialize Vibex MTX and I’m looking forward to playing a pivotal role in that process. A successful launch will enable Antares to continue to build commercial capabilities for the recently announced Vibex QS T, potentially the first auto injector testosterone product for men suffering from symptomatic testosterone deficiency.”

Mr. Jooste joins Antares from Cephalon, Inc., where his most recent position was Vice President Commercial Assessment and New Product Planning. Previously at Cephalon he held leadership positions in sales and marketing as well as commercial operations. LeRoux was with Nabi Biopharmaceuticals as Senior Vice President Global Sales and Marketing and he was the Chief Operating Officer of Aton Pharma where he built the organization from the ground up and managed all aspects of a start-up biotech company developing products to treat cancer. Earlier in his career he held positions with Wyeth Pharmaceuticals and Eli Lilly & Co. LeRoux has new product planning and portfolio management experience in multiple therapeutic areas including endocrinology and rheumatology. His major product launch successes include Prozac®, Ceclor®, Gemzar®, Humulin®, Enbrel® and Effexor XR®. Mr. Jooste received his diploma in Pharmacy from Pretoria Technikon in South Africa, and a Bachelor of Commerce, Economics and Industrial Psychology from the University of South Africa.

About Antares Pharma

Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include Vibex™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors distributed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton® hGH. In the gel-based area, the Company's FDA approved product is Gelnique 3%™ for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for marketing in the U.S. and Canada. Antares’ portfolio includes Elestrin® (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and marketed in the U.S. by Jazz Pharmaceuticals. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the development and manufacturing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate offices and Pharma Group are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company’s transdermal systems and drug/device combination products.

Vistashares Artificial I... (AMEX:AIS)
Historical Stock Chart
From Nov 2024 to Dec 2024

Vistashares Artificial I... (AMEX:AIS)
Historical Stock Chart
From Dec 2023 to Dec 2024